Westfield Capital Management Co. LP Increases Stake in Clovis Oncology, Inc. (CLVS)
Westfield Capital Management Co. LP grew its position in Clovis Oncology, Inc. (NASDAQ:CLVS) by 45.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 459,470 shares of the biopharmaceutical company’s stock after purchasing an additional 144,300 shares during the period. Westfield Capital Management Co. LP owned approximately 0.94% of Clovis Oncology worth $37,860,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its holdings in shares of Clovis Oncology by 0.7% in the second quarter. PNC Financial Services Group Inc. now owns 2,820 shares of the biopharmaceutical company’s stock valued at $265,000 after purchasing an additional 20 shares during the period. Hanseatic Management Services Inc. increased its holdings in shares of Clovis Oncology by 0.3% in the second quarter. Hanseatic Management Services Inc. now owns 13,693 shares of the biopharmaceutical company’s stock valued at $1,282,000 after purchasing an additional 37 shares during the period. Aperio Group LLC increased its holdings in shares of Clovis Oncology by 1.7% in the second quarter. Aperio Group LLC now owns 5,093 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 83 shares during the period. Greenwood Capital Associates LLC grew its holdings in Clovis Oncology by 4.0% during the second quarter. Greenwood Capital Associates LLC now owns 5,485 shares of the biopharmaceutical company’s stock worth $514,000 after acquiring an additional 212 shares during the period. Finally, Amalgamated Bank grew its holdings in Clovis Oncology by 10.4% during the second quarter. Amalgamated Bank now owns 4,811 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 454 shares during the period.
Several analysts recently commented on the company. Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 target price on the stock in a report on Tuesday, October 17th. Oppenheimer reaffirmed a “hold” rating on shares of Clovis Oncology in a report on Tuesday, October 10th. Barclays assumed coverage on Clovis Oncology in a report on Monday, October 23rd. They set an “overweight” rating and a $105.00 target price on the stock. Leerink Swann reaffirmed a “buy” rating and set a $107.00 target price on shares of Clovis Oncology in a report on Monday, September 18th. Finally, BidaskClub lowered Clovis Oncology from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 9th. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Clovis Oncology currently has an average rating of “Buy” and a consensus target price of $86.15.
Clovis Oncology, Inc. (NASDAQ:CLVS) opened at $61.33 on Monday. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94. Clovis Oncology, Inc. has a 1 year low of $35.35 and a 1 year high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.06). The business had revenue of $16.81 million for the quarter, compared to analysts’ expectations of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same quarter in the prior year, the company posted ($1.70) EPS. research analysts anticipate that Clovis Oncology, Inc. will post -7.63 earnings per share for the current year.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $69.50, for a total transaction of $208,500.00. Following the transaction, the insider now owns 191,583 shares in the company, valued at $13,315,018.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 9,000 shares of company stock worth $653,220 in the last quarter. 12.50% of the stock is currently owned by company insiders.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.